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Febrile Neutropenia and Long-term Risk of Infection 
Among Patients Treated With Chemotherapy for 
Malignant Diseases
Josefine Nordvig,1 Theis Aagaard,1 Gedske Daugaard,2,  Peter Brown,3 Henrik Sengeløv,3 Jens Lundgren,1,  and Marie Helleberg1,
1Centre for Health, Immunity and Infections (CHIP), 2Department of Oncology, and 3Department of Haematology, Copenhagen University Hospital, Rigshospitalet, Denmark
Background. Febrile neutropenia (FN) is a common complication to chemotherapy, associated with increased short-term mor-
bidity and mortality. However, the long-term outcomes after FN are poorly elucidated. We examined the long-term risk of infection 
and mortality rates in cancer patients with and without FN.
Methods. Patients aged >16 years treated with firstline chemotherapy were followed from 180 days after initiating chemother-
apy until first infection, a new treatment with chemotherapy, death, or end of follow-up. Risk factors for infections were analyzed 
by competing risks regression, with death or another treatment with chemotherapy as competing events. Adjusted incidence rate 
ratios (aIRRs) of infection and death were analyzed using Poisson regression. In analyses of mortality, infection was included as a 
time-updated variable.
Results. We included 7190 patients with a median follow-up (interquartile range) of 0.58 (0.20–1.71) year. A  total of 1370 
patients had an infection during follow-up. The aIRRs of infection were 1.86 (95% confidence interval [CI], 1.56–2.22) and 2.19 
(95% CI, 1.54–3.11) for patients with 1 or >1 episode of FN compared with those without FN. Mortality rate ratios were 7.52 (95% 
CI, 6.67–8.48) <1 month after, 4.24 (95% CI, 3.80–4.75) 1–3 months after, 2.33 (95% CI, 1.63–3.35) 3–6 months after, and 1.09 (95% 
CI, 0.93–1.29) >6 months after an infection, compared with the time before infection.
Conclusions. FN during chemotherapy is associated with a long-term increased risk of infection. Mortality rates are substan-
tially increased for 6 months following an infection.
Keywords. cancer; chemotherapy; febrile neutropenia; infection; long-term complications.
 
Neutropenia is a frequent and potentially serious complication 
to myelosuppressive chemotherapy among patients treated for 
malignant disease. Patients with moderate or severe neutro-
penia (absolute neutrophil count [ANC], 0.5–1.0  ×  109/L or 
<0.5 × 109/L) have considerably increased risk of serious infec-
tions during the neutropenic episode [1, 2]. Fever (temperature 
>38°C), in addition to neutropenia or febrile neutropenia (FN), 
can be a life-threatening condition in patients on chemotherapy 
as infections in this patient group can progress rapidly.
A number of studies have examined the incidence of chemo-
therapy-induced FN and the associated short-term conse-
quences in terms of treatment delays and dose reductions in 
delivered chemotherapy [3, 4], increased hospital mortality, 
length of hospital stay, and hospital costs [5, 6]. FN is associ-
ated with poorer cancer outcomes, presumably due to reduced 
dose intensity of chemotherapy [7]. However, it has not been 
elucidated whether patients who develop FN during chemo-
therapy have an increased risk of infections in the long term.
It is well recognized that among patients who receive the 
same type and intensity of chemotherapy, only some develop 
serious infections during treatment, indicating that not only 
treatment-related but also patient-related factors are impor-
tant for the short-term risk of infectious complications [8]. We 
hypothesized that FN is a marker of reduced immune compe-
tence and increased susceptibility to infectious complications 
and that this vulnerability also leads to an excess risk of infec-
tions after the chemotherapy has been completed. To test this 
hypothesis, we examined the risk of infection from 180 days 
after initiation of firstline chemotherapy among patients who 
had experienced 1 or more episodes of FN vs patients with 
no FN within the first 180  days after starting chemotherapy. 
Secondarily, we assessed whether the timing of FN in relation 
to initiation of chemotherapy was a predictor of long-term risk 
of infections.
Short-term mortality associated with FN has been well stud-
ied. One study including almost 42 000 patients found the over-
all in-hospital mortality to be 9.5% [5]. However, there are no 
data on mortality associated with late infections emerging in 
the period after chemotherapy. Therefore, we compared mor-
tality rates in patients with vs without infectious events that 
occurred after completion of chemotherapy.
M A J O R  A R T I C L E
© The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases 
Society of America. This is an Open Access article distributed under the terms of the Creative 
Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/
by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any 
medium, provided the original work is not altered or transformed in any way, and that the work 
is properly cited. For commercial re-use, please contact journals.permissions@oup.com
DOI: 10.1093/ofid/ofy255
Received 3 August 2018; editorial decision 27 September 2018; accepted 12 October 2018.
Correspondence: J.  Nordvig, MS, CHIP, University of Copenhagen, Copenhagen, Denmark 
(josefine.nordvig@regionh.dk).
; published online June 15, 2018
D
ow
nloaded from
 https://academ
ic.oup.com
/ofid/article-abstract/5/10/ofy255/5144574 by R
oyal Library C
openhagen U
niversity user on 17 April 2019
2 • OFID • Nordvig et al
Such information may be used to guide the intensity of long-
term monitoring and prophylactic interventions for patients 
with a fragile phenotype and could potentially result in more 
appropriate management of these patients.
METHODS
Study Design and Setting
We conducted a cohort study of patients treated with chemo-
therapy for malignant diseases at Rigshospitalet, University of 
Copenhagen, Denmark, in the period from January 2010 to 
September 2015.
We previously assessed rates of FN among patients treated 
with chemotherapy for malignant disease at our center and 
found incidence rates of 5.7% during the first cycle [9] and 2.1% 
[10] during the following cycles.
Patients and Study Size
We included patients who were >16 years of age and alive 180 days 
after initiating standard firstline chemotherapy. Patients were 
either treated for solid malignant tumors or for diffuse large B-cell 
lymphoma. Exclusion criteria were having been included in a 
trial protocol, treatment regimens with <10 patients per proto-
col, watch-and-wait regimens, and treatment with regimens other 
than firstline (ie, relapse, second- or third-line therapy) (Figure 1).
Data Sources
Data were obtained from electronic health records retrieved from 
the PERSIMUNE data repository (PERSIMUNE Datawarehouse 
[11]). Data on chemotherapy for patients with diffuse large 
B-cell lymphoma were retrieved from the LYFO database [12]. 
The PERSIMUNE Datawarehouse contains nationwide data on 
biochemistry, microbiology, and pathology from all national 
labs and data on diagnoses, hospital admissions, outpatient vis-
its, and causes of death from national registries, as well as data 
on vital signs and medication from central regional databases. As 
such, there is complete ascertainment of outcomes. The LYFO 
database is a nationwide database that has been collecting data 
prospectively since 1982 regarding diagnostics and treatment of 
malignant lymphoma in Denmark [12].
Study Exposure, Outcomes, and Variables
The exposure was FN before baseline. Patients were then grouped 
based on the number of FN episodes (1 or >1). The primary out-
comes of interest were (1) time to first severe infection, defined 
as collection of a blood culture, which was used as a proxy for an 
infection, regardless of whether the culture was positive or nega-
tive, and (2) mortality associated with infectious events.
Secondary Analyses
In a secondary analysis, we grouped the patients according to in 
which cycle of chemotherapy they experienced FN (FN in the 
first cycle, FN in later cycles, or no FN) to test the hypothesis 
that patients who experienced an episode of FN in the first cycle 
have a more fragile phenotype and poorer long-term outcomes 
than patients who experienced FN in later cycles.
Definitions
We defined FN by:
1a. a neutrophilocyte count ≤0.5 × 109/L;
or
1b.  a leukocyte count ≤2.0 × 109/L, where a neutrophilocyte 
count was not measured on the same day (sensitivity, spec-
ificity, and positive and negative predictive values for total 
leucocyte count as a predictor of neutropenia are provided 
in the Supplementary Data: Supplementary Table  1 and 
Supplementary Figure 1);
and
2. either collection of a blood culture, regardless of whether 
the culture was positive or negative, or death within 3 days 
of neutropenia.
Only episodes of FN that occurred at least 7 days after a prior 
episode of FN were considered a new event.
Patients assessed for
inclusion (n = 12 211) Patients excluded (n = 5021)
Exclusion criteria (n = 2284)
– Trial chemotherapy (n = 765)
– <10 patients per treatment (n = 297)
– No active treatment (n = 995)
– Not firstline therapy (n = 227)
Patients treated only with antihormonals (n = 346)
Study population (n = 7190)
•
Patients who died before start of follow-up (n = 2728)•
Patients starting new chemotherapy at the date of start of
follow-up (n = 9)
•
•
Relapse (n = 188)•
Second-line (n = 34)•
Third-line (n = 5)•
Watch-and-wait (n = 649)•
Figure 1. Flowchart showing patient exclusion criteria.
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Statistical Analysis
Baseline was defined as 180 days after initiation of chemother-
apy, and patients were followed until date of first infection, 
date of death, date of another treatment with chemotherapy, 
or September 29, 2015, whichever came first. Patients were 
stratified into 3 groups based on the number of FN episodes 
they had experienced before baseline (none, 1, or >1) on 
firstline chemotherapy. We then estimated the relative risk 
of infection among patients with either 1 or >1 episodes of 
FN vs those without FN. The cumulative risk of infection was 
assessed using competing risks regression based on Fine and 
Gray’s proportional subdistribution hazards model [13], with 
death or another treatment with chemotherapy as competing 
events. The relative risks of infection and death were assessed 
using multivariate Poisson regression analyses adjusted for 
baseline variables: age, sex, diagnosis, calendar year, leucocyte 
count, hemoglobin, serum albumin, body surface area (BSA), 
comorbidities (Charlson’s Comorbidity Index [CCI] [14, 15]), 
and stage of disease. In the analysis of risk of death, date of 
infection was included as a time-updated variable. Missing 
data were included as a separate category in the multivariate 
analyses.
All statistical analyses were performed using the Stata/IC sta-
tistical package, version 14.
The study was approved by the Danish Data Protection 
Agency (RH-2015-04, I-suite 03605) and the Danish National 
Board of Health (3-3013-1060/1/).
RESULTS
Patient Characteristics
A total of 12 211 potentially eligible patients diagnosed with 1 of 
26 types of cancers were evaluated. We excluded 2284 patients 
who received treatment other than standard firstline chemo-
therapy, 2728 patients who died within 180 days of initiation of 
chemotherapy, and 9 patients who received another treatment 
with chemotherapy at the date of start of follow-up, leaving 
7190 patients in the study (Figure 1). The median age at base-
line (interquartile range [IQR]) was 64 (54–71) years, and 3656 
(50.9%) were women (Table  1). The most frequent diagnoses 
were breast cancer (889, 12.4%), colon cancer (850, 11.8%), gas-
tric cancer (829, 11.5%), non–small cell lung cancer (713, 9.9%), 
primary malignant brain tumor (509, 7.1%), nasopharyngeal 
cancer (490, 6.8%), and ovarian cancer (449, 6.2%). There were 
287 (4.0%) patients with diffuse large B-cell lymphoma.
Overall, 736 (10.2%) patients experienced at least 1 episode 
of FN during the first 180 days after initiation of chemotherapy. 
Of those, 617 (8.6%) patients experienced 1 FN episode, and 
119 (1.6%) patients experienced more than 1 FN episode before 
baseline. Out of the 2728 patients who died within 180  days 
of initiation of chemotherapy, 374 (13.7%) had experienced at 
least 1 episode of FN.
Risk of and Risk Factors for Infection
Among the 7190 patients, who were followed for 8486 per-
son-years, with a median follow-up time (IQR) of 0.58 (0.20–
1.71) years, a total of 1370 patients had at least 1 infectious event 
during follow-up. The incidence rates were 15.3 (95% confi-
dence interval [CI], 14.5–16.2), 24.3 (95% CI, 20.7–28.5), and 
26.7 (95% CI, 19.2–37.2) per 100 person-years for the patients 
with no, 1, and >1 FN episode before baseline, respectively. 
Baseline characteristics of patients with and without an infec-
tion during follow-up are presented in the Supplementary Data 
(Supplementary Table 2). Out of the 1370 collected blood cul-
tures, 139 (10.1%) had a positive result (Supplementary Table 3).
The cumulative incidence rates of infection 3  years after 
baseline were 21%, 31%, and 34% for the group with no, 1, or 
>1 FN episode, respectively (Figure 2). The adjusted incidence 
rate ratio (aIRR) of infection was 1.86 (95% CI, 1.56–2.22) and 
2.19 (95% CI, 1.54–3.11) among patients with 1 FN episode 
and those with >1 FN episode compared with those with no 
FN, respectively (Table 2). The excess risk of infection among 
patients with prior FN compared with those without prior FN 
was constant over the time after start of follow-up (data not 
shown).
Age 60–79 years, hypoalbuminemia, anemia or leukocytosis 
at baseline, BSA ≥2 m2, a CCI score ≥3, and disseminated dis-
ease were other independent risk factors for infection (Table 2).
The rates of infection varied between patients with different 
cancer types, with incidence rates (IRs) of 3.35/100PY (95% CI, 
2.59–4.35) to 48.8/100 PY (95% CI, 37.1–64.3) for patients with 
breast cancer and prostate cancer, respectively. However, the 
relative risk of infection for patients with vs without FN before 
baseline showed the same tendency across the different types of 
cancers, with a substantially increased risk among patients with 
prior FN (Supplementary Table  4). Among patients with dif-
fuse large B-cell lymphoma, the IR of infection was 12.0/100PY 
(95% CI, 9.45–15.1), which was similar to the pooled group of 
patients with solid tumors (IR, 16.5/100PY; 95% CI, 15.6–17.4). 
For the group of patients with diffuse large B-cell lymphoma, 
the IRR of infection was 1.91 (95% CI, 1.03–3.53) and 1.93 (95% 
CI, 0.98–3.83) among patients with 1 FN episode and those 
with >1 FN episode compared with those with no FN, respec-
tively. For the pooled group of patients with solid tumors, the 
IRR of infection was 1.59 (95% CI, 1.34–1.90) and 2.00 (95% CI, 
1.35–2.98) among patients with 1 FN episode and those with 
>1 FN episode compared with those with no FN, respectively.
Risk of Death After Infectious Events
There was an increased risk of death after an infectious event, 
and the increased mortality persisted up to 6  months after 
the infection. The adjusted mortality rate ratio (aMRR) was 
7.52 (95% CI, 6.67–8.48) for the first month, 4.24 (95% CI, 
3.80–4.75) for 1–3 months after, 2.33 (95% CI, 1.63–3.35) for 
3–6 months after, and 1.09 (95% CI, 0.93–1.29) for >6 months 
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Table 1. Patient Characteristics
No FN 1 FN Episode >1 FN Episode Total Population P Value
Total, No. (%) 6454 (100.0) 617 (100.0) 119 (100.0) 7190 (100.0)
Female, No. (%) 3220 (49.9) 362 (58.7) 74 (62.2) 3656 (50.9) <.0001
Age, median (IQR), y 64 (54–71) 64 (54–71) 65 (59–72) 64 (54–71)
Age groups, No. (%) .60
<40 y 422 (6.54) 48 (7.78) 9 (7.56) 479 (6.66)
40–59 y 2064 (32.0) 198 (32.1) 26 (21.9) 2288 (31.8)
60–79 y 3675 (56.9) 355 (57.5) 79 (66.4) 4109 (57.2)
80+ y 293 (4.54) 16 (2.59) 5 (4.20) 314 (4.37)
Baseline leukocyte count, No. (%) .06
<3.5 633 (9.81) 91 (14.8) 24 (20.2) 748 (10.4)
3.5–8.8 4368 (67.7) 409 (66.3) 65 (54.6) 4842 (67.3)
>8.8 1278 (19.8) 117 (19.0) 27 (22.7) 1422 (19.8)
Missing values 175 (2.71) 0 (0.0) 3 (2.52) 178 (2.48)
Baseline hemoglobin, No. (%) <.0001
<lower limit of normala 3750 (58.1) 435 (70.5) 79 (66.4) 4264 (59.3)
≥lower limit of normal 2.539 (39.3) 182 (29.5) 36 (30.3) 2757 (38.3)
Missing values 165 (2.56) 0 (0.00) 4 (3.36) 169 (2.35)
Baseline albumin, No. (%)
<lower limit of normalb 1084 (16.8) 154 (25.0) 43 (36.1) 1281 (17.8)
≥lower limit of normal 3020 (46.8) 290 (47.0) 49 (41.2) 3359 (46.7)
Missing values 2.350 (36.4) 173 (28.0) 27 (22.7) 2550 (35.47)
Body surface area, No. (%) .05
<2 m2 4694 (72.7) 462 (74.9) 81 (68.1) 5237 (72.8)
≥2 m2 1542 (23.9) 111 (18.0) 13 (10.9) 1666 (23.2)
Missing 218 (3.38) 44 (7.13) 25 (21.0) 287 (3.99)
Charlson Comorbidity Index, No. (%) <.0001
2 5167 (80.1) 455 (73.7) 79 (66.4) 5701 (79.3)
3 448 (6.94) 55 (8.91) 13 (10.9) 516 (7.18)
4+ 839 (13.0) 107 (17.3) 27 (22.7) 973 (13.5)
Stage of disease at start of chemotherapy, No. (%) <.0001
Adjuvating 1342 (20.8) 112 (18.2) 15 (12.6) 1469 (20.4)
Neo-adjuvating/concomitant 2360 (36.6) 184 (29.8) 18 (15.1) 2562 (35.6)
Inoperable/disseminated/metastatic 2016 (31.2) 219 (35.5) 51 (42.9) 2286 (31.8)
Missing/unknown 736 (11.4) 102 (16.5) 35 (29.4) 873 (12.1)
Diagnosis, No. (%) <.0001
Breast cancer 782 (12.1) 92 (14.9) 15 (12.6) 889 (12.4)
Primary malignant brain tumor 502 (7.78) 7 (1.13) 0 (0.00) 509 (7.08)
Anal cancer 13 (0.20) 2 (0.32) 0 (0.00) 15 (0.21)
Cholangiocarcinoma 25 (0.39) 1 (0.16) 1 (0.84) 27 (0.38)
Colon cancer 833 (12.9) 17 (2.76) 0 (0.00) 850 (11.8)
Esophageal cancer 273 (4.23) 25 (4.05) 2 (1.68) 300 (4.17)
Liver cancer 24 (0.37) 1 (0.16) 0 (0.00) 25 (0.35)
Rectum cancer 163 (2.53) 0 (0.00) 0 (0.00) 163 (2.2)
Gastric cancer 758 (11.7) 54 (8.75) 17 (14.3) 829 (11.5)
Diffuse large B-cell lymphoma 218 (3.38) 44 (7.13) 25 (21.0) 287 (3.99)
Penis cancer 9 (0.14) 0 (0.00) 0 (0.00) 9 (0.13)
Prostate cancer 143 (2.22) 20 (3.24) 5 (4.20) 168 (2.34)
Testicular cancer 145 (2.25) 18 (2.92) 6 (5.04) 169 (2.35)
 Bladder cancer 172 (2.67) 15 (2.43) 0 (0.00) 187 (2.60)
 Cervical cancer 212 (3.28) 16 (2.59) 0 (0.00) 228 (3.17)
 Uterine cancer 131 (2.03) 2 (0.32) 1 (0.84) 134 (1.86)
 Ovary cancer 355 (5.50) 76 (12.3) 18 (15.1) 449 (6.24)
 Vulvar cancer 11 (0.17) 0 (0.00) 0 (0.00) 11 (0.15)
 Nasopharyngeal cancer 402 (6.23) 81 (13.1)  7 (5.88) 490 (6.82)
 Soft tissue sarcoma 5 (0.08) 0 (0.00) 1 (0.84) 6 (0.08)
 Neuroendocrine tumor 119 (1.84) 19 (3.08) 3 (2.52) 141 (1.96)
 Non–small cell lung cancer 628 (9.73) 76 (12.3) 9 (7.56) 713 (9.92)
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after an infection, compared with the time before infection 
(Table 3). The increase in risk of death after an infectious event 
was similar among patients with vs without a prior episode of 
FN (Supplementary Table 5).
Among the 139 patients with positive blood cultures, 39 
(28.1%) and 84 (60.4%) died within 1 and 6 months of the infec-
tion, respectively. For the 1231 patients with negative blood cul-
tures, 240 (19.5%) and 570 (46.3%) died within 1 and 6 months, 
respectively.
Secondary Analyses
We found no significant difference in risk of infection accord-
ing to timing of the episode of FN. The incidence rate of infec-
tion was 15.3 (95% CI, 14.5–16.2) per 100 person-years for the 
patients with no FN, 23.5 (95% CI, 18.8–29.3) for the patients 
with FN in the first cycle of chemotherapy, and 25.7 (95% CI, 
21.3–30.9) for patients with first FN in later cycles of chemo-
therapy. The aIRR of infection was 1.82 (95% CI, 1.43–2.31) 
and 1.98 (95% CI, 1.62–2.42) for the groups with FN in the first 
cycle and later cycles, respectively, compared with the group 
with no FN.
DISCUSSION
In a large cohort study using nationwide data from electronic 
health records, we examined if FN within 180  days after ini-
tiation of chemotherapy is a predictor of long-term risk of 
infection and poor outcomes among cancer patients. We 
found that FN following chemotherapy was associated with a 
long-term increased risk of infection, with an approximately 
2-fold increase in risk among patients who had experienced 
FN compared with patients who had not developed FN within 
180 days after initiation of chemotherapy. An infectious event 
after completion of chemotherapy was associated with a mark-
edly increased risk of death in the following month, and the 
increased risk of death persisted up to 6 months after the infec-
tion. Associations between infection and risk of death did not 
differ between patients with vs without prior episodes of FN.
The observational design of the study precludes assessment 
of causality, but the association between FN and increased 
long-term risk of infection may suggest that patients with FN 
represent a fragile phenotype with a generally increased risk of 
infectious complications and poor long-term outcomes follow-
ing chemotherapy. The association between FN and long-term 
risk of infection was independent of other indicators of a more 
vulnerable phenotype, such as older age, anemia, low albumin, 
disseminated disease, and comorbidity. In fact, the estimate 
of the relative risk of infection associated with FN increased 
slightly after adjustment for these factors.
Existing literature in this area focus on short-term com-
plications of FN in terms of in-hospital mortality, length of 
hospital stay, and hospital costs [2, 5, 7]. Major factors associ-
ated with inpatient mortality, length of stay, and costs include 
patient characteristics, type of malignancy, comorbidities, and 
infectious complications [5]. Identification of well-defined risk 
factors of poor outcome on the long term is equally essential 
for optimizing the management of these patients, which is the 
rationale for this study. However, the literature on long-term 
complications of FN is scarce.
Previous studies have shown that dose reductions and treat-
ment delays in chemotherapy, which are often consequences of 
FN, are associated with reduced long-term survival, presumably 
due to progression of cancer secondary to suboptimal chemo-
therapy [16]. In recent years, the importance of the immune 
system in controlling cancer has been highlighted [17]. The 
impact of chemotherapy dose intensity and of immunological 
parameters on associations between FN after chemotherapy 
and risk of progression of cancer should be explored in future 
studies.
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Figure 2. Cumulative incidence of infection in the period from 180 days after ini-
tiation of chemotherapy, stratified by episodes of febrile neutropenia before base-
line. Abbreviation: FN, febrile neutropenia.
No FN 1 FN Episode >1 FN Episode Total Population P Value
 Malignant pleural mesothelioma 284 (4.40) 13 (2.11) 0 (0.00) 297 (4.13)
 Small cell lung cancer 162 (2.51) 29 (4.70) 9 (7.56) 200 (2.78)
 Thymoma 19 (0.29) 7 (1.13) 0 (0.00) 26 (0.36)
 Cancer of unknown primary 66 (1.02) 2 (0.32) 0 (0.00) 68 (0.95)
Abbreviations: FN, febrile neutropenia; IQR, interquartile range.
aLower limit for normal hemoglobin level was 8.3 for men and 7.3 for women.
bLower limit for normal albumin level was <36 if age <70 years and <34 if age >70 years.
Table 1. Continued
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Our analyses show that older age (>60  years) and baseline 
anemia, hypoalbuminemia, and leukocytosis, as well as comor-
bidity and disseminated disease stage, are independent risk fac-
tors for infections. However, the aIRR for the 80+ age group 
did not reach statistical significance due to the small number of 
patients in this age group. Older age has been associated with 
poor outcomes in previous studies [5, 18]. Serum albumin is a 
commonly used marker for nutritional status in cancer patients. 
Malnutrition and inflammation suppress albumin synthesis, 
and low serum albumin level can therefore reflect the severity 
of disease and has also been shown to be a good predictor of 
prognosis in previous studies [18, 19]. One prospective obser-
vational study also found low albumin (<35  g/L) at baseline 
to be associated with increased risk of FN in the first cycle of 
chemotherapy among patients with non-Hodgkin lymphoma 
[20]. Similarly, it is well known that anemia in cancer patients 
is a significant prognostic factor and has shown to be a strong 
predictor of poorer survival in this patient group [21].
The study has some limitations: We defined episodes of FN 
as collection of a blood culture during a neutropenic episode 
because data on temperature measurements at and during hos-
pital admissions were only available from the most recent part 
Table 2. Incidence Rates and Incidence Rate Ratios of Infection
No. of Events IRa (95% CI) IRR (95% CI) aIRR (95% CI)
FN groups
No FN 1182 15.3 (14.5–16.2) 1 (ref.) 1 (ref.)
1 FN episode 153 24.3 (20.7–28.5) 1.59 (1.34–1.88) 1.86 (1.56–2.22)
>1 FN episode 35 26.7 (19.2–37.2) 1.75 (1.25–2.44) 2.19 (1.54–3.11)
Sex
Female 567 11.4 (10.5–12.3) 1 (ref.) 1 (ref.)
Male 803 22.9 (21.4–24.6) 2.02 (1.81–2.25) 1.11 (0.97–1.28)
Age groups, y
<40 63 7.71 (6.02–9.86) 0.71 (0.54–0.93) 1.05 (0.79–1.41)
40–59 347 10.9 (9.77–12.1) 1 (ref.) 1 (ref.)
60–79 892 21.4 (20.0–22.8) 1.97 (1.74–2.23) 1.16 (1.02–1.33)
>80 68 23.1 (18.2–29.3) 2.13 (1.64–2.76) 1.20 (0.92–1.58)
Baseline leukocyte count
<3.5 119 12.4 (10.3–14.8) 0.86 (0.71–1.04) 0.74 (0.60–0.90)
3.5–8.8 865 14.3 (13.4–15.3) 1 (ref.) 1 (ref.)
>8.8 346 29.3 (26.3–32.5) 2.04 (1.80–2.31) 1.65 (1.45–1.88)
Missing 40 13.3 (9.76–18.13) 0.93 (0.68–1.28) 1.26 (0.45–3.57)
Baseline hemoglobin
<lower limit of normalb 876 18.9 (17.7–20.2) 1.48 (1.32–1.66) 1.26 (1.11–1.43)
≥lower limit of normal 456 12.8 (11.7–14.0) 1 (ref.) 1 (ref.)
Missing 38 13.2 (9.60–18.1) 1.03 (0.74–1.44) 0.83 (0.29–2.41)
Baseline albumin
<lower limit of normalc 269 30.5 (27.1–34.4) 2.03 (1.76–2.35) 1.26 (1.11–1.43)
≥lower limit of normal 635 15.0 (13.9–16.2) 1 (ref.) 1 (ref.)
Missing 466 13.8 (12.6–15.1) 0.92 (0.82–1.04) 0.83 (0.29–2.41)
Body surface area, m2
<2 916 15.1 (14.1–16.1) 1 (ref.) 1 (ref.)
≥2 384 21.1 (19.1–23.3) 1.40 (1.25–1.58) 1.23 (1.08–1.40)
Missing 70 12.0 (9.45–15.1) 0.79 (0.62–1.01) 1
Charlson Comorbidity Index
2 1028 14.4 (13.5–15.3) 1 (ref.) 1 (ref.)
3 127 27.1 (22.8–32.3) 1.89 (1.57–2.27) 1.48 (1.23–1.80)
4+ 215 25.0 (21.9–28.6) 1.74 (1.50–2.02) 1.29 (1.10–1.52)
Stage of disease at start of chemotherapy
Adjuvating 141 5.15 (4.36–6.06) 1 (ref.) 1 (ref.)
Neo-adjuvating/concomitant 479 17.6 (16.1–19.2) 3.41 (2.83–4.12) 2.53 (1.93–3.32)
Inoperable/disseminated/metastatic 530 26.6 (24.4–28.9) 5.17 (4.29–6.23) 4.05 (3.18–5.16)
Missing/unknown 220 21.5 (18.9–24.6) 4.19 (3.39–5.18) 4.79 (3.06–7.50)
Univariate and multivariate Poisson regression analyses. All variables were included in the multivariate model, including all diagnoses.
Abbreviations: aIRR, adjusted incidence rate ratio; CI, confidence interval; FN, febrile neutropenia; IR, incidence rate; IRR, incidence rate ratio.
aIR, per 100 person-years of follow-up.
bLower limit for normal hemoglobin level was 8.3 mmol/L for men and 7.3 mmol/L for women.
cLower limit for normal albumin level was <36 g/L if age <70 years and <34 g/L if age >70 years.
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of the study period. We have tested the validity of this definition 
on the subgroup of patients with data on temperature measure-
ments and found good agreement with the standard definition 
of FN [9]. We also used collection of a blood culture as a proxy 
for later infectious events. It is very difficult to find criteria that 
have both very high sensitivity and specificity for ascertainment 
of infectious events. Microbiological samples are only positive 
in a subset of patients with infections, and the sensitivity of 
analyses of microbiological samples is hampered when patients 
are treated with antibiotics before they present at the hospital.
Standard operating procedure in our center is to only col-
lect blood cultures when there is clinical suspicion of infec-
tion. Thus, we believe that blood culture collection is a relevant 
proxy, which has also previously been used in a previous study 
to define infectious events [22].
We could not rule out that fever (eg, collection of a blood cul-
ture) was due to progression of cancer. In our analyses, patients 
were censored when they received another treatment with 
chemotherapy, and thus the infectious events during follow-up 
are unlikely to represent chemotherapy-induced FN episodes. 
We did not have access to data regarding patient performance 
status, but hemoglobin and albumin might be considered as 
surrogate markers of performance status [18, 19].
Major strengths of the study include the large cohort of 
patients with long-term follow-up and access to precise and 
complete nationwide data on study outcomes through elec-
tronic health records and nationwide registries that could be 
linked using the unique Danish civil registration number.
In conclusion, we found that FN is associated with a long-
term increased risk of infection among patients treated with 
chemotherapy for malignant disease and that an infectious 
event is associated with increased mortality, persisting up to 
6 months after the infection.
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Event vs the Time Before/Without Infection
Time After Infection, mo MR (95% CI) aMRRa (95% CI)
0–1 3.35 (3.00–3.74) 7.52 (6.67–8.48)
1–3 1.62 (1.46–1.79) 4.24 (3.80–4.75)
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> 6 0.28 (0.24–0.33) 1.09 (0.93–1.29)
Abbreviations: aMRR, adjusted mortality rate ratio; CI, confidence interval; MR, mortality rate.
aMortality rate ratio adjusted for age, gender, diagnosis, calendar year, and baseline 
leukocyte count.
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